Feifei Zhang

Jiangxi Key Laboratory Of Oncology
Nanchang, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

NT5DC2 inhibits ferroptosis by stabilizing ACSL3 in bladder cancer.

NT5DC2 inhibits ferroptosis by stabilizing ACSL3 in bladder cancer.

Journal: Cell death discovery

Published: October 24, 2025

SMPD1 modulates malignant progress of osteosarcoma through ferroptosis pathway.

SMPD1 modulates malignant progress of osteosarcoma through ferroptosis pathway.

Journal: Tissue & cell

Published: October 11, 2025

DLST mediates the malignant progression of osteosarcoma cells by regulating the p38 MAPK signaling pathway.

DLST mediates the malignant progression of osteosarcoma cells by regulating the p38 MAPK signaling pathway.

Journal: Biochemical and biophysical research communications

Published: September 25, 2025

Solute carrier family 35 member A2 regulates mitophagy through the PI3K/AKT/mTOR axis, promoting the proliferation, migration, and invasion of osteosarcoma cells.

Solute carrier family 35 member A2 regulates mitophagy through the PI3K/AKT/mTOR axis, promoting the proliferation, migration, and invasion of osteosarcoma cells.

Journal: Gene

Published: October 22, 2023

LncRNA GClnc1 promotes osteosarcoma progression by stabilizing NONO and blocking FBXW7-mediated ubiquitination.

LncRNA GClnc1 promotes osteosarcoma progression by stabilizing NONO and blocking FBXW7-mediated ubiquitination.

Journal: BMC cancer

Published: July 24, 2023

FKBP11 improves the malignant property of osteosarcoma cells and acts as a prognostic factor of osteosarcoma.

FKBP11 improves the malignant property of osteosarcoma cells and acts as a prognostic factor of osteosarcoma.

Journal: Aging

Published: July 20, 2022

The synergistic anticancer effect of the bromodomain inhibitor OTX015 and histone deacetylase 6 inhibitor WT-161 in osteosarcoma.

The synergistic anticancer effect of the bromodomain inhibitor OTX015 and histone deacetylase 6 inhibitor WT-161 in osteosarcoma.

Journal: Cancer cell international

Published: June 06, 2021

HDAC6 inhibitor WT161 performs anti-tumor effect on osteosarcoma and synergistically interacts with 5-FU.

HDAC6 inhibitor WT161 performs anti-tumor effect on osteosarcoma and synergistically interacts with 5-FU.

Journal: Bioscience reports

Published: November 25, 2020

LncRNA GSEC promotes the proliferation, migration and invasion by sponging miR-588/ EIF5A2 axis in osteosarcoma.

LncRNA GSEC promotes the proliferation, migration and invasion by sponging miR-588/ EIF5A2 axis in osteosarcoma.

Journal: Biochemical and biophysical research communications

Published: August 08, 2020

LncRNA SNHG5 promotes the progression of osteosarcoma by sponging the miR-212-3p/SGK3 axis.

LncRNA SNHG5 promotes the progression of osteosarcoma by sponging the miR-212-3p/SGK3 axis.

Journal: Cancer cell international

Published: June 01, 2018

Showing 1-10 of 10

Last Updated: 09/26/2026